The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus.
The TS/A mouse mammary adenocarcinoma is a poorly immunogenic tumor widely used in preclinical models of cancer immunotherapy. CTLs have often been indicated as important in TS/A tumor destruction, but their generation in this model has been rarely studied, nor have their precise target(s) been identified. We hypothesized that the gp70 Env product of an endogenous murine leukemia virus could be a target antigen for TS/A-specific CTLs and investigated this possibility in four different TS/A cell lines engineered with the genes that encode IFN-alpha, IFN-gamma, interleukin-4, and B7.1, respectively. All tumor cell lines expressed gp70, albeit at different levels, as demonstrated by reverse transcription-PCR analysis. Transfected tumor cells exhibited a delayed growth in vivo, and partial tumor regression. Spleen cells from mice that displayed tumor regression had high percentages of CD8(+) T cells that were specifically stained with L(d) tetramers loaded with gp70(423-431), the antigenic epitope of gp70 protein. Mixed leukocyte-peptide and mixed leukocyte-tumor cultures, set up by stimulating splenocytes with the immunogenic peptide and with transfected TS/A tumor cells, respectively, resulted in similar large increases in tetramer-reactive CD8(+) T cells and showed high lytic activity specific for gp70(423-431). Finally, in a Cold Target Inhibition assay, lytic activity of a mixed leukocyte-tumor culture was inhibited in an overlapping fashion by both the TS/A line used for restimulation and 293L(d) cells loaded with gp70(423-431) peptide, but not by 293L(d) cells pulsed with an irrelevant H-2 L(d) epitope, thus demonstrating that all or most of the cytotoxic activity was directed exclusively against this antigenic epitope.
Department of Oncology and Surgical Sciences, University of Padova, Italy. antonio.rosato@unipd.it
Antonio
A
Rosato
Silvia
S
Dalla Santa
Alessia
A
Zoso
Sofia
S
Giacomelli
Gabriella
G
Milan
Beatrice
B
Macino
Valeria
V
Tosello
Paolo
P
Dellabona
Pier-Luigi
PL
Lollini
Carla
C
De Giovanni
Paola
P
Zanovello
D000230:Adenocarcinoma / Q000276:immunology*; D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology; D018122:B7-1 Antigen / Q000096:biosynthesis; D005260:Female; D016056:Immunodominant Epitopes / Q000276:immunology*; D016898:Interferon-alpha / Q000096:biosynthesis; D007371:Interferon-gamma / Q000096:biosynthesis; D015847:Interleukin-4 / Q000096:biosynthesis; D008213:Lymphocyte Activation / Q000276:immunology; D008325:Mammary Neoplasms, Experimental / Q000235:genetics / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D012190:Retroviridae / Q000276:immunology*; D015682:Retroviridae Proteins, Oncogenic / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014162:Transfection; D014759:Viral Envelope Proteins / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*
D000951:Antigens, Neoplasm; D018122:B7-1 Antigen; D016056:Immunodominant Epitopes; D016898:Interferon-alpha; D015682:Retroviridae Proteins, Oncogenic; D014759:Viral Envelope Proteins; D015847:Interleukin-4; D007371:Interferon-gamma